April 3, 2018 / 11:38 AM / a year ago

REFILE-BRIEF-Palatin Technologies Presents Preclinical Data On Investigational Treatment For IBD

1 Min Read

(Corrects headline to say “IBD”, not “IBS”)

April 3 (Reuters) - Palatin Technologies Inc:

* PALATIN TECHNOLOGIES PRESENTS PRECLINICAL ORAL FORMULATION DATA ON PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST FOR INFLAMMATORY BOWEL DISEASES

* PALATIN TECHNOLOGIES INC - SUBJECT DOSING IS ONGOING WITH TOP LINE DATA CURRENTLY EXPECTED IN Q3 OF 2018 FOR PL-8177 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below